%0 Journal Article
%A Lin, Chunqing
%A Slama, Jiri
%A Gonzalez, Paula
%A Goodman, Marc T
%A Xia, Ningshao
%A Kreimer, Aimée R
%A Wu, Ting
%A Hessol, Nancy A
%A Shvetsov, Yurii
%A Ortiz, Ana P
%A Grinsztejn, Beatriz
%A Moscicki, Anna-Barbara
%A Heard, Isabelle
%A Del Refugio González Losa, María
%A Kojic, Erna M
%A Schim van der Loeff, Maarten F
%A Wei, Feixue
%A Longatto-Filho, Adhemar
%A Mbulawa, Zizipho A
%A Palefsky, Joel M
%A Sohn, Annette H
%A Hernandez, Brenda Y
%A Robison, Katina
%A Simpson, Steve
%A Conley, Lois J
%A de Pokomandy, Alexandra
%A van der Sande, Marianne A B
%A Dube Mandishora, Racheal S
%A Volpini, Lays P B
%A Pierangeli, Alessandra
%A Romero, Byron
%A Wilkin, Timothy
%A Franceschi, Silvia
%A Hidalgo-Tenorio, Carmen
%A Ramautarsing, Reshmie A
%A Park, Ina U
%A Tso, Fernanda K
%A Godbole, Sheela
%A D'Hauwers, Kathleen W M
%A Sehnal, Borek
%A Menezes, Lynette J
%A Heráclio, Sandra A
%A Clifford, Gary M
%T Cervical determinants of anal HPV infection and high-grade anal lesions in women: a collaborative pooled analysis.
%D 2019
%U http://hdl.handle.net/10668/14122
%X Cervical cancer screening might contribute to the prevention of anal cancer in women. We aimed to investigate if routine cervical cancer screening results-namely high-risk human papillomavirus (HPV) infection and cytohistopathology-predict anal HPV16 infection, anal high-grade squamous intraepithelial lesions (HSIL) and, hence, anal cancer. We did a systematic review of MEDLINE, Embase, and the Cochrane library for studies of cervical determinants of anal HPV and HSIL published up to Aug 31, 2018. We centrally reanalysed individual-level data from 13 427 women with paired cervical and anal samples from 36 studies. We compared anal high-risk HPV prevalence by HIV status, cervical high-risk HPV, cervical cytohistopathology, age, and their combinations, using prevalence ratios (PR) and 95% CIs. Among 3255 women with anal cytohistopathology results, PRs were similarly calculated for all anal HSIL and HPV16-positive anal HSIL. Cervical and anal HPV infections were highly correlated. In HIV-negative women, anal HPV16 prevalence was 41% (447/1097) in cervical HPV16-positive versus 2% (214/8663) in cervical HPV16-negative women (PR 16·5, 95% CI 14·2-19·2, p HPV-based cervical cancer screening programmes might help to stratify anal cancer risk, irrespective of HIV status. For targeted secondary anal cancer prevention in high-risk groups, HIV-negative women with cervical HPV16, especially those older than 45 years, have a similar anal cancer risk profile to that of HIV-positive women. International Agency for Research on Cancer.
%~